Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
about
Structural Basis for Bulky-Adduct DNA-Lesion Recognition by the Nucleotide Excision Repair Protein Rad14Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancerCis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsThe survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma.Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric studyERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependentPart 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Expression of XPG protein in human normal and tumor tissues.Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based ChemotherapyXPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair arrayGenetic variation in immune regulation and DNA repair pathways and stomach cancer in China.Biomarker-based selection of therapy for colorectal cancer.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.Colorectal Cancer and Alcohol Consumption-Populations to Molecules.Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis.
P2860
Q27705197-6969452F-650E-4735-952B-4A68087570D8Q33406047-0DBAE958-5B77-4E15-9031-EA473B883DA5Q33947765-502713AD-4D4F-46F6-B905-2045F466EE97Q34008793-2854C076-4DDF-4C95-AD75-98BC27EF310CQ34401264-F325F404-8A99-4EC4-810F-BF91685E1E41Q34669169-6080B8D4-AD99-4B8F-BCC7-8178D8EDEC97Q34694410-FAF0496C-FCDB-48CB-B593-75C2EF7E4444Q35535744-3C12C7ED-5B97-40FC-9DDE-2BC419575AEDQ35584647-296D9876-2A9C-469A-A40E-DB70B31A002FQ36529982-8D379FBE-60FD-4D70-9A53-D05F9F182CCCQ36993563-A4F8387F-BF07-448C-ABC5-0A64AC1DDC74Q36998361-0FE493E2-1188-4205-B22E-B07B36647FA6Q37287450-BE7EBE52-0B4D-497F-9C8F-574C066EEA4CQ37301347-C86772FB-4417-4B3B-9514-AABCAC071016Q37886995-538FE7D4-0740-45E2-922F-0FCA7BDA1D43Q37969851-F50869E0-4E62-40F6-8B0F-B09E30A486DAQ38835268-1F77A331-6D2E-4DCC-B5C5-370538260C4DQ42837601-464203DD-D7A5-4827-8F1C-625AAFD7C1FAQ48132576-12ABE051-68C3-432F-8CF0-AD9A877234FAQ48259649-6988B46A-414A-46C9-B8D2-73CF9F06453FQ49359901-4444A062-CB53-46C8-84F2-55DE659FDAE0
P2860
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@ast
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@en
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@nl
type
label
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@ast
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@en
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@nl
prefLabel
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@ast
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@en
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@nl
P2093
P356
P1433
P1476
Single nucleotide polymorphism ...... oxaliplatin/fluoropyrimidine.
@en
P2093
Francisco Martinez
Isabel Moreno
Jose Moreno
Mariano Monzo
Marta Navarro-Vigo
Rafael Ibeas
Raquel Hernandez
Rosa Artells
P2860
P304
P356
10.1159/000113534
P577
2007-01-01T00:00:00Z